Join Growin Stock Community!

Erasca, inc.ERAS.US Overview

US StockHealthcare
(No presentation for ERAS)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

ERAS AI Insights

ERAS Overall Performance

ERAS AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

ERAS Recent Performance

1.98%

Erasca, inc.

0.05%

Avg of Sector

-0.31%

S&P500

ERAS PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

ERAS Key Information

ERAS Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

ERAS Profile

Erasca, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead candidates include ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. It is also developing ERAS-801, a central nervous system-penetrant EGFR inhibitor for the treatment of patients with recurrent glioblastoma multiforme. The company was incorporated in 2018 and is headquartered in San Diego, California.

Price of ERAS

ERAS FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

ERAS Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-0.41
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
12.15
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-0.41
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
12.15
Price-to-FCF
-
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%

  • When is ERAS's latest earnings report released?

    The most recent financial report for Erasca, inc. (ERAS) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating ERAS's short-term business performance and financial health. For the latest updates on ERAS's earnings releases, visit this page regularly.

  • How much debt does ERAS have?

    As of the end of the reporting period, Erasca, inc. (ERAS) had total debt of 48.29M, with a debt ratio of 0.11. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.

  • How much cash does ERAS have?

    At the end of the period, Erasca, inc. (ERAS) held Total Cash and Cash Equivalents of 70.64M, accounting for 0.17 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • What is the FCF of ERAS?

    Erasca, inc. (ERAS)'s Free Cash Flow (FCF) for the period is -21.66M, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 3.39% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.